Prometrium Label Updates 2020 to 2026: What Changed and Why It Matters

Direct answer

Prometrium's current safety architecture rests on two things that have not meaningfully changed since the 1990s: the peanut-oil-related contraindication and the class-wide Black Box Warning inherited from WHI and WHIMS data on combined estrogen-progestin therapy. The FDA has updated pregnancy and lactation labeling format across the industry (the PLLR transition), and progestogen-class labels have generally been refined over time to reflect newer pharmacovigilance and drug-interaction data. However, a specific year-by-year list of Prometrium label edits between 2020 and 2026, with exact percentages and hazard ratios, cannot be confirmed from the sources available for this article. Anyone relying on a claimed label detail for prescribing or counseling should verify the exact current text at Drugs@FDA or DailyMed rather than trusting a secondary summary, including this one.

What Prometrium is, so it isn't confused with related products

Prometrium is oral micronized progesterone, a bioidentical progestogen suspended in peanut oil to improve absorption, taken by mouth. It is FDA-approved for two indications: prevention of endometrial hyperplasia in postmenopausal women who have a uterus and are taking estrogen, and treatment of secondary amenorrhea. It is not the same product as vaginal micronized progesterone preparations (such as Crinone or Endometrin), compounded progesterone creams or troches, or synthetic progestins like medroxyprogesterone acetate (Provera). Pharmacokinetics, labeled warnings, and dosing differ across these formulations, so label language written for oral Prometrium does not automatically apply to a vaginal or compounded alternative.

How FDA labels change, in general

The FDA requires a manufacturer to file a supplement whenever it wants to revise labeling. A Prior Approval Supplement needs FDA sign-off before the new language can be used; a Changes Being Effected (CBE-30) supplement can go into effect 30 days after filing unless FDA objects. Changes to Warnings and Precautions or Contraindications sections typically receive more scrutiny. Triggers for a label change generally include new trial data, signals from spontaneous adverse event reports in FAERS, findings from FDA's Sentinel System (an active surveillance system drawing on health insurance claims and electronic health record data), or agency-wide policy shifts such as the PLLR transition. This is standard FDA process, not a Prometrium-specific claim, and it is documented on FDA's own pages on Sentinel and MedWatch/FAERS.

The trial data the label rests on, and what is genuinely established versus what needs a primary-source check

Three research programs are consistently cited as the scientific backdrop for Prometrium's labeling:

• The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (mid-1990s), which compared lipid effects of different progestin regimens added to estrogen. It is widely cited as showing a more favorable lipid profile with micronized progesterone than with medroxyprogesterone acetate. The exact quantitative lipid difference should be checked against the original JAMA publication rather than assumed from a secondary source.
• The Women's Health Initiative (WHI) combined hormone therapy trial, which found increased rates of cardiovascular events, stroke, venous thromboembolism, and invasive breast cancer in women taking conjugated equine estrogen plus medroxyprogesterone acetate compared with placebo. This is the trial that generated the class-wide Black Box Warning applied to all combined estrogen-progestogen products, including Prometrium, even though Prometrium itself was not the progestogen studied in WHI.
• The WHI Memory Study (WHIMS), an ancillary WHI study in women aged 65 and older, which reported a roughly doubled rate of probable dementia in the combined hormone therapy group compared with placebo. This finding underlies the dementia language in the Black Box Warning.

These three trials are genuinely well known in the menopause and hormone therapy literature. What is not verified here is the precise numeric figures sometimes attached to them in secondary write-ups (specific hazard ratios, exact percentage differences, exact patient-year incidence rates). A clinician who needs the exact figures for a discussion with a patient should pull them from the original JAMA publications or from the current FDA label rather than from this article.

An important nuance genuinely reflected in current hormone therapy thinking, though it requires the original trial population to be stated carefully: WHI and WHIMS studied conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin, not micronized progesterone. Whether the same magnitude of cardiovascular, breast cancer, and dementia risk applies to micronized progesterone-containing regimens is an active area of research and is not settled by WHI itself. Some observational and smaller randomized data suggest possible differences in venous thromboembolism and breast cancer signal by progestogen type, but this evidence sits below the level of a large randomized outcomes trial like WHI, and the FDA has not removed or downgraded the class-wide Black Box Warning for Prometrium on this basis as of this writing. Any claim that Prometrium's label now formally "distinguishes" its cardiovascular or breast cancer risk from WHI's findings should be verified against the current Drugs@FDA text before being repeated to a patient, because that is a specific regulatory claim this draft could not confirm.

Pregnancy and lactation labeling: a confirmed structural change

One change that is well documented at the regulatory level, independent of Prometrium specifically, is the FDA's Pregnancy and Lactation Labeling Rule (PLLR), finalized in 2014 with a phased compliance timeline for drugs approved before mid-2001. Prometrium, approved in 1998, falls into the cohort affected by this transition. Under PLLR, the old A/B/C/D/X pregnancy letter categories were retired in favor of narrative subsections: 8.1 Pregnancy, 8.2 Lactation, and 8.3 Females and Males of Reproductive Potential, each with a risk summary, clinical considerations, and supporting data discussion (FDA PLLR final rule). This is a format change required across many older drug labels, not evidence that the underlying pregnancy risk assessment for Prometrium changed. The exact current wording of Prometrium's Section 8 should be read directly from the label rather than paraphrased.

Bedtime dosing and sedation: a real mechanism, unverified specifics

Oral micronized progesterone undergoes first-pass hepatic metabolism into neuroactive steroid metabolites, including allopregnanolone, which modulates GABA-A receptors and can cause drowsiness. This is a recognized, mechanistically plausible reason that oral micronized progesterone labeling generally advises evening dosing and warns about drowsiness and dizziness. Specific pharmacokinetic figures sometimes cited for this effect (for example, a precise fold-difference in allopregnanolone levels between oral and vaginal administration) should be checked against a specific, correctly identified pharmacokinetic study before being used in patient counseling, since this draft could not confirm which published study those particular numbers came from.

Drug interactions: CYP3A4 is the right mechanism, exact numbers need verification

Progesterone is metabolized substantially through CYP3A4. It is pharmacologically reasonable, and consistent with general CYP3A4 drug-interaction principles, that strong CYP3A4 inducers (such as rifampin) could lower progesterone exposure and that strong CYP3A4 inhibitors (such as ketoconazole) could raise it. Whether the current Prometrium label states a specific percentage change in exposure, and what that percentage is, should be confirmed against the current label text or the specific pharmacokinetic study being cited. A precise number without a verifiable source is not something this draft will assert.

The peanut oil contraindication: consistently reported and low-risk to state plainly

Prometrium capsules use peanut oil as the delivery vehicle for micronized progesterone. A known or suspected peanut allergy has been treated as a contraindication to oral Prometrium since its original approval, and this detail is consistent across sources describing the product, including the current label available through Drugs@FDA. Patients with a peanut allergy who need progestogen therapy should discuss alternative formulations, such as compounded preparations in a different vehicle or non-oral progestogen products, with their prescriber, understanding that compounded products carry a different regulatory status (see below).

Endometrial protection and secondary amenorrhea dosing

Prometrium's two FDA-approved indications use different dosing regimens: a cyclic regimen for endometrial protection in postmenopausal women taking estrogen, and a separate regimen for secondary amenorrhea. The exact milligram amounts and number of days are label-specific details that can be revised, so a reader making a clinical decision should confirm the current regimen directly from the FDA label or DailyMed rather than from a secondary summary, including the version circulating in earlier drafts of this article. General statements that continuous, non-cyclic dosing has not been studied or approved for endometrial protection are consistent with how progestogen-add-back regimens are typically labeled, but the precise current wording should still be checked.

Compounded micronized progesterone is a different regulatory category

Compounded progesterone preparations (oral, vaginal, or topical) are commonly used in practice but are not FDA-approved products. They do not go through the same safety and efficacy review as Prometrium, and the FDA has stated that compounded drugs generally lack the assurance of quality, safety, and effectiveness that comes with an approved application (FDA compounding Q&A). Dosing guidance, contraindications, and warning language written for Prometrium do not automatically transfer to a compounded formulation, particularly vaginal preparations, which generally have lower systemic absorption than oral dosing. This is a meaningful clinical distinction and a genuine reason to avoid treating compounded progesterone data as interchangeable with Prometrium's label.

Post-market surveillance: what FDA monitors, and what this draft cannot confirm

FDA monitors approved drugs after launch through FAERS (spontaneous adverse event reports from clinicians, patients, and manufacturers) and the Sentinel System (active surveillance using claims and electronic health record data across a large population of covered lives). Both systems are real and ongoing (Sentinel, MedWatch). Whether FAERS generated a new safety signal for Prometrium specifically between 2020 and 2024, and whether any particular Sentinel-based cohort study changed label language, is not something this draft can confirm from the sources available. A reader who needs that answer should search FDA's public FAERS dashboard directly rather than rely on a secondary claim.

Evidence boundary: what is established, what is plausible, what is not confirmed

Established: Prometrium's 1998 approval, its two indications, the peanut oil vehicle and related contraindication, the class-wide Black Box Warning tied to WHI and WHIMS in combined estrogen-progestin products, and the general FDA processes for label revision (Prior Approval Supplements, CBE-30, PLLR format).

Plausible but not fully settled by primary evidence available here: that micronized progesterone carries a meaningfully different cardiovascular, venous thromboembolism, or breast cancer risk profile than synthetic progestins such as medroxyprogesterone acetate at the population level. Some data point this direction, but WHI itself did not study micronized progesterone, and the current label's Black Box Warning has not been narrowed on this basis as far as this draft can confirm.

Not established by the sources available for this article: a specific, dated, year-by-year list of Prometrium label revisions from 2020 through 2026, including exact percentages, hazard ratios, and quoted trial conclusions. Readers should treat any such detailed timeline, including earlier versions of this page, as requiring direct verification against Drugs@FDA and DailyMed before being cited or repeated.

A verification framework for reading any Prometrium label-history summary

Use this sequence before relying on a claim about what Prometrium's label currently says or when it changed:

1. Is the claim about current label content or about label history? Current content questions ("does the label contraindicate peanut allergy?") can be answered directly from the label text on Drugs@FDA or DailyMed. History questions ("did the cardiovascular warning change in 2024?") require checking the supplement history and comparing archived label versions side by side, both available through Drugs@FDA.
2. Does the claim carry a specific number? If a source states an exact hazard ratio, percentage, or patient count, trace it to the named trial and check that the trial actually reports that figure for that population. A number without a traceable source, or attached to a mismatched citation, should not be repeated to a patient or used in a clinical note.
3. Is the population the same as the one you care about? WHI and WHIMS studied conjugated equine estrogen plus medroxyprogesterone acetate in specific age ranges. A finding from that trial does not automatically transfer to oral micronized progesterone, to younger women, or to non-oral routes. Check the population before applying the conclusion.
4. Is this an approved indication, off-label use, or a compounded product? Prometrium's label covers oral capsules for endometrial protection and secondary amenorrhea. Vaginal micronized progesterone, compounded formulations, and other off-label uses are not covered by this label and should not be evaluated against it.
5. When in doubt, go to the primary regulatory source. Drugs@FDA shows submission dates and supplement numbers so you can identify exactly when a section changed. DailyMed typically reflects FDA-approved changes within days. If a secondary article's claim cannot be located in either source, treat it as unverified rather than authoritative.

When to involve a clinician urgently

Anyone taking Prometrium who develops sudden chest pain, shortness of breath, one-sided weakness or vision change, leg swelling with warmth or redness, new severe headache, or signs of an allergic reaction (difficulty breathing, facial or throat swelling, widespread hives) should seek urgent medical care rather than waiting for a routine follow-up. These symptoms overlap with the cardiovascular and thromboembolic risks named in the Black Box Warning and are not something to evaluate through a label-history article.

References

• FDA, Pregnancy and Lactation Labeling (Drugs) Final Rule: https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule
• FDA, Drugs@FDA database: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
• FDA, Compounding and FDA Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA, Sentinel Initiative: https://www.sentinelinitiative.org/ and https://www.fda.gov/safety/fdas-sentinel-initiative
• FDA, MedWatch Safety Information and Adverse Event Reporting: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
• DailyMed, National Library of Medicine: https://dailymed.nlm.nih.gov/dailymed/

Editorial and medical review note: quantitative assertions regarding prometrium clinical trial outcomes (hazard ratios, percentages, patient counts) and a granular 2020-2026 regulatory revision sequence that were present in the previous version could not be substantiated through verified primary documentation during this revision and have accordingly been limited, conditioned, or excluded. Validate current prescribing information language directly via Drugs@FDA and DailyMed, and provide appropriately correlated PubMed or peer-reviewed journal references for any clinical trial data prior to publication and qualified reviewer approval.